

Instructions to Authors

General Policy. ANTICANCER RESEARCH (AR) will accept original high quality works and reviews on all aspects of experimental and clinical cancer research. The Editorial Policy suggests that priority will be given to papers advancing the understanding of cancer causation, and to papers applying the results of basic research to cancer diagnosis, prognosis, and therapy. AR will also accept the following for publication: (a) Abstracts of scientific meetings on cancer, following consideration and approval by the Editorial Board; (b) Announcements of meetings related to cancer research; (c) Short reviews (of approximately 120 words) and announcements of newly received books and journals related to cancer, and (d) Announcements of awards and prizes.

The principal aim of AR is to provide for the prompt publication of original works of high quality, generally within 1-2 months from final acceptance. Manuscripts will be accepted on the understanding that they report original unpublished works on the cancer problem that are not under consideration for publication by another journal, and that they will not be published again in the same form. All material submitted to AR will be subject to review, when appropriate, by two members of the Editorial Board and by one suitable outside referee. The Editors reserve the right to improve manuscripts on grammar and style.

The Editors and Publishers of AR accept no responsibility for the contents and opinions expressed by the contributors. Authors should warrant due diligence in the creation and issuance of their work.

NIH Open Access Policy. The journal acknowledges that authors of NIH funded research retain the right to provide a copy of the final manuscript to the NIH four months after publication in ANTICANCER RESEARCH, for public archiving in PubMed Central.

Copyright. Once a manuscript has been published in ANTICANCER RESEARCH, which is a copyrighted publication, the legal ownership of all published parts of the paper has passed from the Author(s) to the journal. Material published in the journal may not be reproduced or published elsewhere without written consent of the Managing Editor.

Format. Two types of papers may be submitted: (i) Full papers containing completed original work, and (ii) short papers. Additionally, the Editors may invite review articles concerning fields of recognisable progress. Papers should contain all essential data in order to make the presentation clear. Reasonable economy should be exercised with respect to the number of tables and illustrations used. Papers should be written in clear, concise English. Spelling should follow that given in the "Shorter Oxford English Dictionary".

Manuscripts. Submitted manuscripts should not exceed fourteen (14) pages (approximately 250 words per double - spaced typed page), including abstract, text, tables, figures, and references (corresponding to 4 printed pages). Papers exceeding four printed pages will be subject to excess page charges. All manuscripts should be divided into the following sections:

(a) First page including the title of the presented work [not exceeding fifteen (15) words], full names and full postal addresses of all Authors, name of the Author to whom proofs are to be sent, key words, an abbreviated running title, an indication "clinical", "epidemiological", or "experimental" study, and the date of submission. (Note: The order of the Authors is not necessarily indicative of their contribution to the work. Authors may note their individual contribution(s) in the appropriate section(s) of the presented work); (b) Abstract not exceeding 150 words, organized according to the following headings: Background/Aim - Materials and Methods/Patients and Methods - Results - Conclusion; (c) Introduction; (d) Materials and Methods/Patients and Methods; (e) Results; (f) Discussion; (g) Acknowledgements; (h) References. All pages must be numbered consecutively. Footnotes should be avoided. Review articles may follow a different style according to the subject matter and the Author's opinion. Review articles should not exceed 35 pages (approximately 250 words per double-spaced typed page) including all tables, figures, and references.

Figures. All figures (whether photographs or graphs) should be clear, high contrast, glossy prints of the size they are to appear in the journal: 8.00 cm (3.15 in.) wide for a single column; 17.00 cm (6.70 in.) for a double column; maximum height: 20.00 cm (7.87 in.). Graphs must be submitted as photographs made from drawings and must not require any artwork, typesetting, or size modifications. Symbols, numbering and lettering should be clearly legible. The number and top of each figure must be indicated on the reverse side. Original karyotypes and photographs should be provided wherever possible, and not photographic copies. Colour plates are charged.

Tables. Each table should be submitted on a separate page, typed double-spaced. Tables should be numbered with Roman numerals and should include a short title.

Nomenclature and Abbreviations. Nomenclature should follow that given in "Chemical Abstracts". Standard abbreviations will be preferable. If a new abbreviation is used, it must be defined at its first usage.

References. Citations for the reference sections of submitted works should follow the standard form of "Index Medicus" and must be numbered consecutively. In the text, references should be cited by number. Examples: 1 Sumner AT: The nature of chromosome bands and their significance for cancer research. *Anticancer Res* 1: 205-216, 1981. 2 McGuire WL and Chamnes GC: Studies on the oestrogen receptor in breast cancer. In: *Receptors for Reproductive Hormones* (O' Malley BW, Chamnes GC (eds.). New York, Plenum Publ Corp., pp 113-136, 1973.

Clinical Trials. Authors of manuscripts describing clinical trials should provide the appropriate clinical trial number in the correct format in the text.

For International Standard Randomised Controlled Trials (ISRCTN) Registry (a not-for-profit organization whose registry is administered by Current Controlled Trials Ltd.) the unique number must be provided in this format: ISRCTNXXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by "ISRCTN"). Please note that there is no space between the prefix "ISRCTN" and the number. Example: ISRCTN47956475.

For Clinicaltrials.gov registered trials, the unique number must be provided in this format: NCTXXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by 'NCT'). Please note that there is no space between the prefix 'NCT' and the number. Example: NCT00001789.

Submission of Manuscripts. Follow the Instructions to Authors regarding the format of your manuscript and references. There are 3 ways to submit your article (NOTE: Please use only one of the 3 options. Do not send your articles twice.):

1. To submit your article online please visit: IIAR-Submissions (<http://www.iar-anticancer.org/submissions/login.php>)
2. You can send your article via e-mail to journals@iiar-anticancer.org. Please remember to always indicate the name of the journal you wish to submit your paper. The text should be sent as a Word document (*.doc) attachment. Tables, figures and cover letter can also be sent as e-mail attachments.
3. You can send the manuscript of your article via regular mail in a USB stick, DVD, CD or floppy disk (including text, tables and figures) together with three hard copies of your manuscript to the following address:

John G. Delinassios
International Institute of Anticancer Research (IIAR)
Editorial Office of ANTICANCER RESEARCH,
IN VIVO, CANCER GENOMICS and PROTEOMICS.
1st km Kapandritiou-Kalamou Road
P.O. Box 22, GR-19014 Kapandriti, Attiki
GREECE

Submitted articles will not be returned to Authors upon rejection.

Galley Proofs. Unless otherwise indicated, galley proofs will be sent to the first-named Author of the submission. Corrections of galley proofs should be limited to typographical errors.

Reprints. Twenty-five copies of each communication will be provided free-of-charge. Additional copies or PDF files may be ordered after the acceptance of the paper. Requests for additional reprints should be addressed to the Editorial Office.

Copyright © 2011 - International Institute of Anticancer Research (J.G. Delinassios). All rights reserved (including those of translation into other languages). No part of this journal may be reproduced, stored in a retrieval system, or transmitter in any form or by any means, electronic, mechanical, photocopying, microfilming, recording or otherwise, without written permission from the Publisher.

22th ANNUAL MEETING OF THE ITALIAN SOCIETY OF URO-ONCOLOGY (SIUrO)

Bologna, June 13-15, 2012
Savoia Hotels, Via del Pilastro, 2
Bologna, Italy

Deadline for abstract submission: February 3, 2012

Chair

Giuseppe Martorana

Advisory Committee

Alessandro Bertaccini
Eugenio Brunocilla
Marco Garofalo
Fabio Manferrari
Riccardo Schiavina

Organizing Secretariat

Emilia Viaggi Congressi & Meeting S.r.l.
Via Porrettana, 76
40033 Casalecchio di Reno (BO)
Tel.: + 39 051 6194911
Fax: + 39 051 6194900
e-mail: evcongressi@emiliaviaggi.it
web: www.emiliaviaggi.it

Scientific Secretariat

Societ Italiana di Urologia Oncologica (SIUrO)
c/o Clinica Urologica, Alma Mater Studiorum
Universit di Bologna
Policlinico S. Orsola Malpighi
Padiglione Palagi, via P. Palagi,
9 – 40138 Bologna
Tel.: +39 051 6362421, 051 302082
Fax: +39 051 308037
e-mail: congresso@siuro.it
web: www.siuro.it

**Italian Society of Uro-Oncology
(SIUrO)
President: Giuseppe Martorana,
Bologna, Italy**



CANCER GENOMICS & PROTEOMICS

www.iar-anticancer.org, www.iarjournals.org

Print ISSN: 1109-6535

Online ISSN: 1790-6245

VOL. 1 (2004), VOL. 2 (2005), VOL. 3 (2006), VOL. 4 (2007),
VOL. 5 (2008), VOL. 6 (2009), VOL. 7 (2010), VOL. 8 (2011)

General Policy. CANCER GENOMICS & PROTEOMICS (CGP) welcomes submissions of original high quality articles and reviews on all aspects of the application of genomic and proteomic technologies to experimental and clinical cancer research. The journal's scientific spectrum includes: (a) molecular causes of carcinogenesis, cancer progression and metastasis; (b) structural and functional aspects of genes in the cancer cell; (c) advances in genomic and proteomic technologies applicable to cancer research; (d) anticancer drug design and drug development.

CGP will also accept abstracts and proceedings of scientific meetings for publication, following consideration and approval by the Editorial Board. A main aim of CGP is to ensure the prompt and confidential review, and rapid publication of original works and reviews, generally within 1-3 months from submission or 1-2 months from acceptance.

CGP is published bimonthly by the **International Institute of Anticancer Research** and is available online with **Stanford University HighWire Press**: For more information please visit our websites www.iar-anticancer.org and www.iarjournals.org.

Editorial Office

International Institute of Anticancer Research, 1st km Kapandritiou-Kalamou Rd., P.O. Box 22, Kapandriti, Attiki 19014, Greece. Tel: +30 22950 52945, Fax: +30 22950 53389

e-mail: journals@iar-anticancer.org (Editorial Office); IAR websites: www.iar-anticancer.org and www.iarjournals.org

Free specimen copies of CGP are available on request.

A Selection of Recent Papers

Meta-data Analysis as a Strategy to Evaluate Individual and Common Features of Proteome Changes in Breast Cancer. O. ZAKHARCHENKO, C. GREENWOOD, A. LEWANDOWSKA, U. HELLMAN, L. ALLDRIDGE, S. SOUCHELNITSKYI (*Stockholm; Uppsala, Sweden; Chelmsford, UK; Olsztyn, Poland; Gold Coast, QLD, Australia*)

Circadian Transcription Profile of Mouse Breast Cancer under LD and DD Conditions. E.-Y. OH, X. YANG, A. FRIEDMAN, C.M. ANSELL, J. DU-QUITON, D.F. QUITON, P.A. WOOD, W.J.M. HRUSHESKY (*Columbia, SC; St. Louis, MO, USA*)

Interleukin 6/Interleukin 6 Receptor Interaction and its Role as a Therapeutic Target for Treatment of Cachexia and Cancer. U.H. WEIDLE, S. KLOSTERMANN, D. EGGLE, A. KRÜGER (*Munich, Germany*)

A Biotin Label-based Antibody Array for High-content Profiling of Protein Expression. R. HUANG, W. JIANG, J. YANG, Y.Q. MAO, Y. ZHANG, W. YANG, D. YANG, B. BURKHOLDER, R.F. HUANG, R.-P. HUANG (*Norcross, GA, USA; Guangzhou, P.R. China*)

TGF- β 1 Interactome: Metastasis and Beyond. M. PERERA, C.S. TSANG, R.J. DISTEL, J.N. LACY, L. OHNO-MACHADO, V. RICCHIUTI, L.P. SAMARANAYAKE, G.B. SMEJKAI, M.G. SMITH, A.J. TRACHTENBERG, W.P. KUO (*Hong Kong, Hong Kong; Boston, MA; Ormond Beach, FL; La Jolla, CA, USA*)

Epigenetic Inactivation of the Placentally Imprinted Tumor Suppressor Gene TFPI2 in Prostate Carcinoma. T. RIBARSKA, M. INGENWERTH, W. GOERING, R. ENGERS, W.A. SCHULZ (*Düsseldorf, Germany*)

Molecular Profiling Using Tissue Microarrays as a Tool to Identify Predictive Biomarkers in Laryngeal Cancer Treated with Radiotherapy. G. HOLLGERSSON, S. EKMAN, J. REIZENSTEIN, M. BERGQVIST, F. PONTÉN, M. UHLÉN, K. MAGNUSSON, P. JONNALAGADDA, A. ASPLUND, S. STRÖMBERG, A. LINDER, E. BLOMQUIST, M. LILJEHOLM, B. LÖDÉN, K. HELLSTRÖM, S. BERGSTRÖM (*Uppsala; Örebro; Gävle; Karlstad; Stockholm; Sweden; Mumbai, India*)

Proteomic Study of Sera from Patients with Bladder Cancer: Usefulness of S100A8 and S100A9 Proteins. S. MINAMI, Y. SATO, T. MATSUMOTO, T. KAGEYAMA, Y. KAWASHIMA, K. YOSHIO, J.-I. ISHII, K. MATSUMOTO, R. NAGASHIO, I. OKAYASU (*Kanagawa, Japan*)

Analysis of Protein Phosphorylation in Cisplatin-treated Human Cells Following Annexin V-based Separation and Multi-Antibody Screening. E. O'MEARA, S. CRUET-HENNEQUART, M.P. CARTY (*Galway, Ireland*)

Identification of Melanoma Antigens Using a Serological Proteome Approach (SERPA). A. SUZUKI, A. IIZUKA, M. KOMIYAMA, M. TAKIKAWA, A. KUME, S. TAI, C. OHSHITA, A. KURUSU, Y. NAKAMURA, A. YAMAMOTO, N. YAMAZAKI, S. YOSHIKAWA, Y. KIYOHARA, Y. AKIYAMA (*Shizuoka; Tokyo; Saitama, Japan*)

DNA-based Assay for EPHB6 Expression in Breast Carcinoma Cells as a Potential Diagnostic Test for Detecting Tumor Cells in Circulation. B.P. FOX, R.P. KANDPAL (*Pomona, CA, USA*)

Discovery of Serum Protein Biomarkers for Prostate Cancer Progression by Proteomic Analysis. J.A. ALRUWAILI, S.ET. LARKIN, B.A. ZEIDAN, M.G. TAYLOR, C.N. ADRA, C.L. AUKIM-HASTIE, P.A. TOWNSEND (*Hampshire, UK; Riyadh, Kingdom of Saudi Arabia; Boston, MA, USA*)

Effects of Artesunate on Cytokinesis and G2/M Cell Cycle Progression of Tumour Cells and Budding Yeast. L. STEINBRÜCK, G. PEREIRA, T. EFFERTH (*Heidelberg; Mainz, Germany*)

Use of NG2 (7.1) in AML as a Tumor Marker and its Association with a Poor Prognosis. K. PETROVICI, M. GRAF, K. HECHT, S. REIF, K. PFISTER, H. SCHMETZER (*Regensburg; Munich, Germany*)

| | |
|---|------|
| Salvage Chemotherapy for Ovarian Carcinoma Recurring During or After Consolidation Chemotherapy with Paclitaxel. Y. MIYOSHI, Y. UEDA, A. MORIMOTO, T. YOKOYAMA, S. MATSUZAKI, E. KOBAYASHI, KIMURA TOSHIHIRO, K. YOSHINO, M. FUJITA, T. ENOMOTO, KIMURA TADASHI (<i>Suita, Osaka, Japan</i>) | 4613 |
| Clinical Significance of <i>BRAF</i> Gene Mutations in Patients with Non-small Cell Lung Cancer. M. KOBAYASHI, M. SONOBE, T. TAKAHASHI, A. YOSHIZAWA, M. ISHIKAWA, R. KIKUCHI, K. OKUBO, C.-L. HUANG, H. DATE (<i>Kyoto, Japan</i>) | 4619 |
| Weekly Paclitaxel in Combination with Doxifluridine for Peritoneally Disseminated Gastric Cancer with Malignant Ascites. I. TAKEYOSHI, F. MAKITA, S. IWAZAKI, H. ISHIKAWA, S. KAKINUMA, Y. SATO, T. OHYA, K. NAKAGAMI, N. TOMIZAWA, M. IZUMI, I. KOBAYASHI, Y. TANAHASHI, J. KOBAYASHI, N. KAMOSHITA, S. KAWATE, Y. SUNOSE, I. SAKAMOTO, D. YOSHINARI, T. YAMADA, T. OKABE (<i>Maebashi; Shibukawa; Tatebayashi; Takasaki; Gunma; Fujiyoshida, Yamanashi; Usui; Koriyama, Fukushima; Ojiya, Niigata; Ogawa, Saitama; Suto, Kumamoto, Japan</i>) | 4625 |
| The Prognostic Significance of HER2 Overexpression in Non-small Cell Lung Cancer. M. TAKENAKA, T. HANAGIRI, S. SHINOHARA, T. KUWATA, Y. CHIKAIISHI, S. OKA, Y. SHIGEMATSU, Y. NAGATA, H. SHIMOKAWA, M. NAKAGAWA, H. URAMOTO, T. SO, F. TANAKA (<i>Kitakyushu, Japan</i>) | 4631 |
| Single-agent Paclitaxel in Advanced Anal Cancer after Failure of Cisplatin and 5-Fluorouracil Chemotherapy. A. ABBAS, E. NEHME, M. FAKIH (<i>Buffalo, NY; Ann Arbor, MI, USA</i>) | 4637 |
| Clinical Characteristics and Treatment Outcomes of Hepatocellular Carcinoma with Inferior Vena Cava/Heart Invasion. Y.H. CHUN, S.H. AHN, J.Y. PARK, D.Y. KIM, K.-H. HAN, C.Y. CHON, S.J. BYUN, S.U. KIM (<i>Seoul, South Korea</i>) | 4641 |
| Clinical Significance of Hypermethylation Status in NSCLC: Evaluation of a 30-Gene Panel in Patients with Advanced Disease. M. PESEK, M. KOPECKOVA, L. BENESOVA, A. MESZAROSOVA, P. MUKENSNABL, F. BRUHA, M. MINARIK (<i>Pilsen; Prague, Czech Republic</i>) | 4647 |
| Growth Factors and Breast Tumors, Comparison of Selected Growth Factors with Traditional Tumor Markers. R. KUCERA, M. CERNA, A. NARSANSKA, S. SVOBODOVA, M. STRAKOVA, J. VRZALOVA, R. FUCHSOVA, I. TRESKOVA, T. KYDLICEK, V. TRESKA, L. PECEN, O. TOPOLCAN, P. PAZDIORA (<i>Pilsen; Prague, Czech Republic</i>) | 4653 |
| Multi-center Phase II Study of FLOX for Advanced Colorectal Cancer Patients in Japan: SWIFT 3 Study. T. KATO, N. NAGATA, M. FUJII, H. TAKEMOTO, K. KONDO, Y. OKUYAMA, H. TOMINAGA, J. SAKAMOTO, H. MISHIMA (<i>Hyogo; Kitakyushu; Osaka; Sakai; Nagoya; Kyoto; Hiroshima, Japan</i>) | 4657 |
| Low Dihydropyrimidine Dehydrogenase Correlates with Prolonged Survival in Patients with Lung Adenocarcinoma Treated with 5-Fluorouracil. Y. SHINTANI, M. INOUE, Y. FUNAKOSHI, A. MATSUMURA, M. OHTA, H. MAEDA, M. OKUMURA (<i>Osaka, Japan</i>) | 4665 |
| Index | 4673 |

* Reviews (pages 4083, 4359, 4369, 4387)

| | |
|---|------|
| Continuous Administration of EGFR-TKIs Following Radiotherapy after Disease Progression in Bone Lesions for Non-small Cell Lung Cancer. M. INOMATA, T. SHUKUYA, T. TAKAHASHI, A. ONO, Y. NAKAMURA, A. TSUYA, H. KENMOTSU, T. NAITO, H. MURAKAMI, H. HARADA, M. ENDO, N. YAMAMOTO (<i>Shizuoka; Toyama; Tokyo, Japan</i>) | 4519 |
| Hypersensitivity Reactions Associated with Platinum-containing Antineoplastic Agents for Thoracic Malignancies. M. TAMIYA, H. KUHARA, T. HIRASHIMA, Y. KONDO, M. SANTO, N. MORISHITA, H. SUZUKI, S. SASADA, N. OKAMOTO, M. KOBAYASHI, I. KAWASE (<i>Osaka; Tokyo, Japan</i>)..... | 4525 |
| Carbonic Anhydrase IX, Hypoxia-inducible Factor-1 α , Ezrin and Glucose Transporter-1 as Predictors of Disease Outcome in Rectal Cancer: Multivariate Cox Survival Models following Data Reduction by Principal Component Analysis of the Clinicopathological Predictors. E.A. KORKEILA, J. SUNDSTRÖM, S. PYRHÖNEN, K. SYRJÄNEN (<i>Turku, Finland</i>) | 4529 |
| Retrospective Study of Patients with Brain Metastases from Melanoma Receiving Concurrent Whole-brain Radiation and Temozolomide. N. DEVITO, M. YU, R. CHEN, E. PAN (<i>Tampa, FL, USA</i>) | 4537 |
| Perioperative Non-tumorous Factors Associated with Survival in HCC Patients Who Underwent Hepatectomy. A. NANASHIMA, T. ABO, K. HAMASAKI, K. WAKATA, T. TOMINAGA, S. HIDAKA, H. TAKESHITA, T. NAGAYASU (<i>Nagasaki, Japan</i>) | 4545 |
| Initial Experience with Hepatic Intraarterial Fotemustine and Interferon Alpha 2b Combination for Treatment of Liver Tumors. F.V. VITALE, P. ROMEO, E.M. DI MAGGIO, A. PARISI, E. MALAPONTE, S. CALÌ, F. VASTA, V. PANEBIANCO, D. ARCORIA, F. FERRAÛ (<i>Taormina; Catania, Italy</i>) | 4553 |
| Prospective Study Evaluating the Plasma Concentrations of Twenty-six Cytokines and Response to Morphine Treatment in Cancer Patients. C. MAKIMURA, T. ARAO, H. MATSUOKA, M. TAKEDA, H. KIYOTA, J. TSURUTANI, Y. FUJITA, K. MATSUMOTO, H. KIMURA, M. OTSUKA, A. KOYAMA, C.K. IMAMURA, T. YAMANAKA, K. TANAKA, K. NISHIO, K. NAKAGAWA (<i>Osaka, Sakai; Habikino, Osaka; Tokyo; Fukuoka, Japan</i>) | 4561 |
| Impact of Chemotherapy for Colorectal Cancer on Regulatory T-Cells and Tumor Immunity. K. MAEDA, S. HAZAMA, K. TOKUNO, S. KAN, Y. MAEDA, Y. WATANABE, R. KAMEI, Y. SHINDO, N. MAEDA, K. YOSHIMURA, S. YOSHINO, M. OKA (<i>Yamaguchi, Japan</i>) | 4569 |
| Radiofrequency Ablation for Intrahepatic Cholangiocarcinoma: Retrospective Analysis of a Single Centre Experience. A. GIORGIO, G. CALISTI, G. DE STEFANO, N. FARELLA, A. DI SARNO, F. AMENDOLA, U. SCOGNAMIGLIO, V. GIORGIO (<i>Naples; Rome, Italy</i>) | 4575 |
| Trans-Arterial Chemoembolization of Metastatic Colorectal Carcinoma to the Liver Adopting DC Bead®, Drug-eluting Bead Loaded with Irinotecan: Results of a Phase II Clinical Study. C. ALIBERTI, G. FIORENTINI, P.C. MUZZIO, F. POMERRI, M. TILLI, S. DALLARA, G. BENEÀ (<i>Padova; Pesaro; Ferrara, Italy</i>) | 4581 |
| Docetaxel, Nedaplatin, and S-1 (DGS) Chemotherapy for Advanced Esophageal Carcinoma: A Phase I Dose-escalation Study. Y. TANAKA, K. YOSHIDA, S. OSADA, K. YAMAGUCHI, T. TAKAHASHI (<i>Gifu City, Gifu, Japan</i>) | 4589 |
| Long-term Survival Following Resection of Brain Metastases from Pancreatic Cancer. J. LEMKE, T.F.E. BARTH, M. JUCHEMS, T. KAPAPA, D. HENNE-BRUNS, M. KORNMANN (<i>Ulm, Germany</i>) | 4599 |
| Comparison of Lymphangiogenesis between Primary Colorectal Cancer and Corresponding Liver Metastases. A. SCHOPPMANN, D. TAMANDL, B. HERBERGER, F. LANGLE, P. BIRNER, S. GELEFF, T. GRÜNBERGER, S.F. SCHOPPMANN (<i>Vienna, Austria</i>) | 4605 |

| | |
|--|------|
| Immunohistochemical Study of VEGF Expression in Oral Squamous Cell Carcinomas: Correlation with the mTOR-HIF-1 α Pathway. T. NARUSE, G. KAWASAKI, S. YANAMOTO, A. MIZUNO, M. UMEDA (Nagasaki, Japan) | 4429 |
| Oxaliplatin, Irinotecan and Cetuximab in Advanced Gastric Cancer. A Multicenter Phase II Trial (Gastric-2) of the Arbeitsgemeinschaft Medikamentöse Tumortherapie (AGMT). E. WÖLL, R. GREIL, W. EISTERER, O. BECHTER, M.A. FRIDRIK, B. GRÜNBERGER, A. ZABERNIGG, B. MAYRBAURL, G. RUSS, M. DLASKA, P. OBRIST, J. THALER (Zams; Salzburg; Innsbruck; Linz; Vienna; Kufstein; Wels, Austria) | 4439 |
| PCA3 Score vs PSA Free/Total Accuracy in Prostate Cancer Diagnosis at Repeat Saturation Biopsy. P. PEPE, F. ARAGONA (Catania, Italy) | 4445 |
| The EMT Status in the Primary Tumor Does Not Predict Postoperative Recurrence or Disease-free Survival in Lung Adenocarcinoma. Y. CHIKAIISHI, H. URAMOTO, F. TANAKA (Kitakyushu, Japan) | 4451 |
| Correlation between <i>IDHI</i> Gene Mutation Status and Survival of Patients Treated for Recurrent Glioma. S. LV, E. TEUGELS, J. SADONES, E. QUARTIER, M. HUYLEBROUCK, S. DU FOUR, M. LE MERCIER, O. DE WITTE, I. SALMON, A. MICHOTTE, J. DE GRÈVE, B. NEYNS (Brussels, Belgium) | 4457 |
| Effect of Maintenance Chemotherapy with Gemcitabine and Paclitaxel on Recurrent Squamous Cell Carcinoma of the Bladder: A Case Report. Y. MIYATA, S.-I. WATANABE, H. TAKAHASHI, Y. SAGARA, T. MATSUO, K. OHBA, H. SAKAI (Nagasaki, Japan) | 4465 |
| External Validation of a Laparoscopic-based Score to Evaluate Resectability for Patients with Advanced Ovarian Cancer Undergoing Interval Debulking Surgery. E. CHEREAU, V. LAVOUE, M. BALLESTER, C. COUTANT, F. SELLE, A. CORTEZ, E. DARAI, J. LEVEQUE, R. ROUZIER (Paris; Rennes, France) | 4469 |
| Anaplastic Oligodendroglial Tumors Harboring 1p/19q Deletion Can Be Successfully Treated without Radiotherapy. Y. IWADATE, T. MATSUTANI, N. SHINOZAKI, N. SAEKI (Chiba City, Chiba, Japan) | 4475 |
| Synchronous Double Tumor of Breast Cancer and Gastrointestinal Stromal Tumor in a Patient with Neurofibromatosis Type 1: Report of a Case. H. TAKEUCHI, S. HIROSHIGE, K. HASHIMOTO, T. KUSUMOTO, Y. YOSHIKAWA, Y. MUTO (Beppu, Japan) | 4481 |
| Clinical and Histopathological Profile of Primary or Secondary Osteosarcoma of the Jaws. F. ANGIERO, F. MOLTRASIO, G. CATTORETTI, M.G. VALENTE (Genoa; Milan, Italy) | 4485 |
| The Cancer Stem Cell Antigens CD133, BCRP1/ABCG2 and CD117/c-KIT Are Not Associated with Prognosis in Resected Early-stage Non-small Cell Lung Cancer. E. HERPEL, K. JENSEN, T. MULEY, A. WARTH, P.A. SCHNABEL, M. MEISTER, F.J.F. HERTH, H. DIENEMANN, M. THOMAS, S. GOTTSCHLING (Heidelberg, Germany) | 4491 |
| Evidence for Acute Vascular Toxicity of Cisplatin-based Chemotherapy in Patients with Germ Cell Tumour. K.-P. DIECKMANN, W.J. STRUSS, U. BUDDE (Hamburg, Germany) | 4501 |
| Circulating CD95-ligand as a Potential Prognostic Marker for Recurrence in Patients with Synchronous Colorectal Liver Metastases. F.J.H. HOOGWATER, N. SNOEREN, M.W. NIJKAMP, A.C. GUNNING, W.J. VAN HOUTD, M.T. DE BRUIJN, E.E. VOEST, R. VAN HILLEGERSBERG, O. KRANENBURG, I.H.M. BOREL RINKES (Utrecht, Netherlands) | 4507 |
| Dissection of Unsuspectious Para-aortic Lymph Nodes Does Not Improve Prognosis of Advanced Endometrial Carcinoma with Intra- or Extra-abdominal Metastasis. Y. UEDA, M. OKAZAWA, T. ENOMOTO, T. EGAWA-TAKATA, KIMURA TOSHIHIRO, K. YOSHINO, M. FUJITA, Y. OHTA, S. KAMIURA, KIMURA TADASHI (Osaka, Japan) | 4513 |

| | |
|---|------|
| Differential Cytotoxic Effects of Sodium Meta-arsenite on Human Cancer Cells, Dental Papilla Stem Cells and Somatic Cells Correlate with Telomeric Properties and Gene Expression. B.-G. JEON, B.M KUMAR, E.-J. KANG, G.-H. MAENG, Y.-M. LEE, Y.-S. HAH, S.-A OCK, D.-O. KWACK, B.-W. PARK, G.-J. RHO (Jinju, Republic of Korea) | 4315 |
| Genome-wide Identification of Chemosensitive Single Nucleotide Polymorphism Markers in Gastric Cancer. Y.J. HA, S.N. YOON, Y.J. JEON, D.H. CHO, S.A. ROH, B.S. KIM, H.J. KIM, S.Y. KIM, Y.S. KIM, J.C. KIM (Seoul; Daejeon; Gyeonggi-Do, Republic of Korea)..... | 4329 |
| De-alcoholization of Paclitaxel Injection for Clinical Application. I. TSUKIYAMA, M. TAKEUCHI, F. ABE, T. KISI, H. SAITO, Y. OBAYASHI, K. WATANABE, A. WAKATSUKI, K.-I. MIYAMOTO, T. HASEGAWA (Aichi-gun, Aichi; Kanazawa, Ishikawa, Japan) | 4339 |
| Modulation of PGE2-induced EP4 Expression on <i>Snail</i> Signaling and the Impact on Epithelial-Mesenchymal Transition: Significance of EP4 Antagonism. H.N. KIM, N.K. NARAYANAN, S. LASANO, B. NARAYANAN (Tuxedo, NY, USA) | 4347 |
| <i>Clinical Studies</i> | |
| * Review: Impact of Cyclooxygenase-2 in Breast Cancer. F. HOELLEN, K. KELLING, C. DITTMER, K. DIEDRICH, M. FRIEDRICH, M. THILL (Luebeck; Krefeld, Germany) | 4359 |
| * Review: Estrogen Pathway Polymorphisms and Mammographic Density. I. DUMAS, C. DIORIO (Quebec City, QC, Canada) | 4369 |
| * Review: Targeting AKT Protein Kinase in Gastric Cancer. K. ALMHANNA, J. STROSBERG, M. MALAFA (Tampa, FL, USA) | 4387 |
| Feasibility of Image-guided Radiotherapy Based on Tomotherapy for the Treatment of Locally Advanced Anal Carcinoma. N.P. NGUYEN, J. VOCK, T. SROKA, R. KHAN, S. JANG, A. CHI, M. BETZ, L. EWELL, D. COHEN, R.P. VO, M. MILLS, V. VINH-HUNG (Galveston, TX, USA; Bern; Geneva, Switzerland) | 4393 |
| Primary Peritoneal Carcinoma in Complete Remission: a Case Report. J. RAMOS, K.S. GUNTURU, S. KRISHNAMOORTHY, B. KENNEY, M.W. SAIF (New Haven, CT; New York, NY, USA)..... | 4397 |
| Loss of p27 ^{KIP1} Expression in Fully-staged Node-negative Breast Cancer: Association with Lack of Hormone Receptors in T1a/b, but not T1c Infiltrative Ductal Carcinoma. D. MIRCHANDANI, D.F. ROSES, G. INGHIRAMI, A. ZELENIUCH-JACQUOTTE, J. CANGIARELLA, A. GUTH, R.A. SAFYAN, S.C. FORMENTI, M. PAGANO, F. MUGGIA (New York, NY, USA) | 4401 |
| Triple Induction Chemotherapy and Chemoradiotherapy for Locally Advanced Esophageal Cancer. A Phase II Study. W. EISTERER, A. DE VRIES, D. KENDLER, B. SPECHTENHAUSER, A. KÖNIGSRÄINER, H. NEHODA, I. VIRGOLINI, P. LUKAS, O. BECHTER, E. WÖLL, D. ÖFNER (Innsbruck; Feldkirch; Kufstein; St. Johann; Zams; Salzburg, Austria; Tübingen, Germany) | 4407 |
| Intraepidermal Nerve Fibre Density in Cancer Patients Receiving Adjuvant Chemotherapy. M.J. KOSKINEN, A.-L. KAUTIO, M.L. HAANPÄÄ, H.K. HAAPASALO, P.-L. KELLOKUMPU-LEHTINEN, T. SAARTO, A.J. HIETAHARJU (Tampere; Helsinki, Finland) | 4413 |
| First Study of Oral Artenimol-R in Advanced Cervical Cancer: Clinical Benefit, Tolerability and Tumor Markers. F. H. JANSEN, I. ADOUBI, K.C. COMOË, T. DE CNODDER, N. JANSEN, A. TSCHULAKOW, T. EFFERTH (Abidjan, Côte d'Ivoire; Liège, Belgium; Mainz, Germany) | 4417 |
| Impaired Bone Microenvironment: Correlation between Bone Density and Presence of Disseminated Tumor Cells. B. KRAEMER, R. ROTHMUND, M. BANYS, N. KRAWCZYK, E.-F. SOLOMAYER, C. MACK, D. WALLWIENER, T. FEHM (Tuebingen; Hamburg; Homburg, Germany)..... | 4423 |

| | |
|--|------|
| Prognostic Significance of N-Cadherin Expression in Oral Squamous Cell Carcinoma. M. DI DOMENICO, G.M. PIERANTONI, A. FEOLA, F. ESPOSITO, L. LAINO, A. DE ROSA, R. RULLO, M. MAZZOTTA, M. MARTANO, F. SANGUEDOLCE, L. PERILLO, L. D'ANGELO, S. PAPAGERAKIS, S. TORTORELLA, P. BUFO, L. LO MUZIO, G. PANNONE, A. SANTORO (<i>Naples; Foggia; Bari, Italy; Ann Arbor, MI, USA</i>) | 4211 |
| Circulating Tumor Cells and “Suspicious Objects” Evaluated Through CellSearch® in Metastatic Renal Cell Carcinoma. A. GRADILONE, R. IACOVELLI, E. CORTESI, C. RAIMONDI, W. GIANNI, C. NICOLAZZO, A. PETRACCA, A. PALAZZO, F. LONGO, L. FRATI, P. GAZZANIGA (<i>Rome, Italy</i>)..... | 4219 |
| Resveratrol Reduces TNF- α -induced U373MG Human Glioma Cell Invasion through Regulating NF- κ B Activation and uPA/uPAR Expression. J. RYU, B.M. KU, Y.K. LEE, J.Y. JEONG, S. KANG, J. CHOI, Y. YANG, D.H. LEE, G.S. ROH, H.J. KIM, G.J. CHO, W.S. CHOI, N. KIM, S.S. KANG (<i>Jinju; Gimhae; Seoul, South Korea</i>)..... | 4223 |
| Quantitative Structure-Activity Relationship (QSAR) Analysis of Tumor-specificity of 1,2,3,4-Tetrahydroisoquinoline Derivatives. Y. UESAWA, K. MOHRI, M. KAWASE, M. ISHIHARA, H. SAKAGAMI (<i>Tokyo; Matsuyama; Saitama, Japan</i>) | 4231 |
| Cytoskeleton Network and Cellular Migration Modulated by Nuclear-localized Receptor Tyrosine Kinase ROR1. H.-C. TSENG, H.-W. KAO, M.-R. HO, Y.-R. CHEN, T.-W. LIN, P.-C. LYU, W.-C. LIN (<i>Hsinchu; Taipei, Taiwan, ROC</i>)..... | 4239 |
| Novel Cytotoxic Isolated from Jamaican Hyptis verticillata jacq Induces Apoptosis and Overcomes Multidrug Resistance. Y. WHITE, T. HAMADA, M. YOSHIMITSU, M. NAKASHIMA, M. HACHIMAN, T. KOZAKO, K. MATSUSHITA, K. UOZUMI, S. SUZUKI, H. KOFUNE, T. FURUKAWA, N. ARIMA (<i>Kagoshima; Fukuoka, Japan</i>)..... | 4251 |
| IGF1Ec Expression in MG-63 Human Osteoblast-like Osteosarcoma Cells. A. PHILIPPOU, A. ARMAKOLAS, Z. PANTELEAKOU, N. PISSIMISSIS, A. NEZOS, A. THEOS, M. KAPARELOU, N. ARMAKOLAS, S.G. PNEUMATICOS, M. KOUTSILIERIS (<i>Athens, Greece</i>) | 4259 |
| Mutations of Mitochondrial DNA as Potential Biomarkers in Breast Cancer. F.F. CAI, C. KOHLER, B. ZHANG, W.J. CHEN, Z. BAREKATI, H.S.P. GARRITSEN, P. LENNER, P. TONIOLO, J.J. ZHANG, X.Y. ZHONG (<i>Basel; Lausanne, Switzerland; Braunschweig, Germany; Umeä, Sweden; Hefei, Anhui, PR China</i>) | 4267 |
| Differential CD133 Expression Pattern during Mouse Colon Tumorigenesis. V. ARENA, E. CAREDDA, V. CUFINO, E. STIGLIANO, F. SCALDAFERRI, A. GASBARRINI, A. CITTADINI, A. SGAMBATO (<i>Rome, Italy</i>)..... | 4273 |
| The Expression of Ki-67, but Not Proliferating Cell Nuclear Antigen, Predicts Poor Disease Free Survival in Patients with Adenocarcinoma of the Lung. S. OKA, H. URAMOTO, H. SHIMOKAWA, T. IWANAMI, F. TANAKA (<i>Kitakyushu, Japan</i>)..... | 4277 |
| Synergism from the Combination of Oxaliplatin with Selected Phytochemicals in Human Ovarian Cancer Cell Lines. N.M. YUNOS, P. BEALE, J.Q. YU, F. HUQ (<i>Kepong, Malaysia; Sydney, NSW, Australia</i>) | 4283 |
| Investigation of Cell Death Induced by N-Methyl-N-Nitrosourea in Cell Lines of Human Origin and Implication of RNA Binding Protein Alterations. A. KORYLLOU, M. PATRINOUGEOURGA, A. DIMOZI, S.A. KYRTOPOULOS, V. PLETSIA (<i>Athens, Greece</i>)..... | 4291 |
| Association of p53 and CDKN1A Genotypes with Endometriosis. T.-H. YING, C.-J. TSENG, S.-J. TSAI, S.-C. HSIEH, H.-Z. LEE, Y.-H. HSIEH, D.-T. BAU (<i>Taichung, Taiwan, ROC</i>) | 4301 |
| Human Brain Endothelial Cell-derived COX-2 Facilitates Extravasation of Breast Cancer Cells Across the Blood-brain Barrier. K.Y. LEE, Y.-J. KIM, H. YOO, S.H. LEE, J.B. PARK, H.J. KIM (<i>Goyang; Daejeon, Republic of Korea</i>) | 4307 |

| | |
|--|------|
| Characterization of T-Cell Memory Phenotype after <i>In Vitro</i> Expansion of Tumor-infiltrating Lymphocytes from Melanoma Patients. J. ZHOU, P. NAGARKATTI, Y. ZHONG, M. NAGARKATTI (<i>Columbia, SC, USA</i>) | 4099 |
| Effects of Artemisinin Dimers on Rat Breast Cancer Cells <i>In Vitro</i> and <i>In Vivo</i> . N.P. SINGH, H.C. LAI, J.S. PARK, T.E. GERHARDT, B.J. KIM, S. WANG, T. SASAKI (<i>Seattle, WA, USA</i>) | 4111 |
| Histone-modifier Gene Expression Profiles Are Associated with Pathological and Clinical Outcomes in Human Breast Cancer. N. PATANI, W.G. JIANG, R.F. NEWBOLD, K. MOKBEL (<i>London; Cardiff, Wales, UK</i>) | 4115 |
| <i>PINCH</i> mRNA Overexpression in Colorectal Carcinomas Correlated with <i>VEGF</i> and <i>FAS</i> mRNA Expression. Z.Y. ZHANG, Y.F. TIAN, Y.Y. WANG, L.J. ZHANG, Z.R. ZHAO, X.F. SUN (<i>Tangshan; Shijiazhuang, PR China; Linköping, Sweden</i>) | 4127 |
| ERCC1 Expression and Outcomes in Head and Neck Cancer Treated with Concurrent Cisplatin and Radiation. M. HAYES, C. LAN, J. YAN, Y. XIE, T. GRAY, R.H. AMIRKHAN, J.E. DOWELL (<i>Miramar Beach, FL; Modesto, CA; Dallas, TX, USA</i>) | 4135 |
| Treatment of Bone Metastasis in Prostate Cancer: Efficacy of a Novel Polybisphosphonate. F. DAUBINE, R. LE BOT, M. MÁRQUEZ, S. NILSSON, T. SCHRÖDER, A.R. HOLMBERG (<i>Nantes, France; Stockholm, Sweden</i>)..... | 4141 |
| <i>REG4</i> , <i>NEIL2</i> , and <i>BIRC5</i> Gene Expression Correlates with Gamma-radiation Sensitivity in Patients with Rectal Cancer Receiving Radiotherapy. T. KOBUNAI, T. WATANABE, T. FUKUSATO (<i>Tokyo, Japan</i>) | 4147 |
| Overexpressed HER2 in NSCLC Is a Possible Therapeutic Target of EGFR Inhibitors. N. ISE, K. OMI, D. NAMBARA, S. HIGASHIYAMA, K. GOISHI (<i>Tokyo; Ehime, Japan</i>) | 4155 |
| Acridine Orange Inhibits Pulmonary Metastasis of Mouse Osteosarcoma. H. SATONAKA, K. KUSUZAKI, K. AKEDA, M. TSUJII, T. IINO, T. UEMURA, T. MATSUBARA, T. NAKAMURA, K. ASANUMA, A. MATSUMINE, A. SUDO (<i>Tsu City, Mie; Kyoto City, Kyoto, Japan</i>) | 4163 |
| Effects of Inorganic and Organic Arsenic Compounds on Growth and Apoptosis of Human T-Lymphoblastoid Leukemia Cells. E. HIKITA, M. ARAI, S. TANAKA, K. ONDA, H. UTSUMI, B. YUAN, H. TOYODA, T. HIRANO (<i>Hachioji; Tokyo, Tokyo; Sagami-hara, Kanagawa, Japan</i>) | 4169 |
| Mutational Screening of <i>RET</i> , <i>HRAS</i> , <i>KRAS</i> , <i>NRAS</i> , <i>BRAF</i> , <i>AKT1</i> , and <i>CTNNB1</i> in Medullary Thyroid Carcinoma. H.-J. SCHULTEN, J. AL-MAGHRABI, K. AL-GHAMDI, S. SALAMA, S. AL-MUHAYAWI, A. CHAUDHARY, O. HAMOUR, A. ABUZENADAH, M. GARI, M. AL-QAHTANI (<i>Jeddah, Saudi Arabia</i>) | 4179 |
| Inactivated Orf virus (<i>Parapoxvirus ovis</i>) Induces Antitumoral Activity in Transplantable Tumor Models. H.-H. FIEBIG, A. SIEGLING, H.-D. VOLK, A. FRIEBE, P. KNOLLE, A. LIMMER, O. WEBER (<i>Freiburg; Wuppertal; Bonn, Germany</i>) | 4185 |
| Expression of the Apoptosis-related Genes <i>Bcl-2</i> and <i>p53</i> in Clinical Samples from Endometrial Carcinoma Patients. I. GONZÁLEZ-RODILLA, V. VERNA, A.-B. MUÑOZ, J. ESTÉVEZ, M. BOIX, J. SCHNEIDER (<i>Santander, Spain</i>)..... | 4191 |
| Yeast-derived Beta-(1-3),(1-6)-D-glucan Induces Up-regulation of CD86 on Dectin-1 ^{positive} Human B-Lymphoma Cell Lines. U. HARNACK, U. KELLERMANN, G. PECHER (<i>Berlin, Germany</i>)..... | 4195 |
| Thioridazine Induces Apoptosis of Multidrug-resistant Mouse Lymphoma Cells Transfected with the Human <i>ABC1</i> and Inhibits the Expression of P-Glycoprotein. G. SPENGLER, J. MOLNAR, M. VIVEIROS, L. AMARAL (<i>Szeged, Hungary; Lisboa, Portugal; Brussels, Belgium</i>) | 4201 |
| Reliability of Direct Sequencing of EGFR: Comparison between Cytological and Histological Samples from the Same Patient. P. BRUNO, S. MARIOTTA, A. RICCI, E. DURANTI, D. SCOZZI, A. NOTO, R. MANCINI, E. GIARNIERI, M.R. GIOVAGNOLI (<i>Rome, Italy</i>) | 4207 |